Activation of [gamma]-globin gene expression by GATA1 and NF-Y in hereditary persistence of fetal hemoglobin

Hereditary persistence of fetal hemoglobin (HPFH) ameliorates [beta]-hemoglobinopathies by inhibiting the developmental switch from [gamma]-globin (HBG1/HBG2) to [beta]-globin (HBB) gene expression. Some forms of HPFH are associated with [gamma]-globin promoter variants that either disrupt binding m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature genetics 2021-08, Vol.53 (8), p.1177
Hauptverfasser: Doerfler, Phillip A, Feng, Ruopeng, Li, Yichao, Palmer, Lance E, Porter, Shaina N, Bell, Henry W, Crossley, Merlin, Pruett-Miller, Shondra M, Cheng, Yong, Weiss, Mitchell J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hereditary persistence of fetal hemoglobin (HPFH) ameliorates [beta]-hemoglobinopathies by inhibiting the developmental switch from [gamma]-globin (HBG1/HBG2) to [beta]-globin (HBB) gene expression. Some forms of HPFH are associated with [gamma]-globin promoter variants that either disrupt binding motifs for transcriptional repressors or create new motifs for transcriptional activators. How these variants sustain [gamma]-globin gene expression postnatally remains undefined. We mapped [gamma]-globin promoter sequences functionally in erythroid cells harboring different HPFH variants. Those that disrupt a BCL11A repressor binding element induce [gamma]-globin expression by facilitating the recruitment of nuclear transcription factor Y (NF-Y) to a nearby proximal CCAAT box and GATA1 to an upstream motif. The proximal CCAAT element becomes dispensable for HPFH variants that generate new binding motifs for activators NF-Y or KLF1, but GATA1 recruitment remains essential. Our findings define distinct mechanisms through which transcription factors and their cis-regulatory elements activate [gamma]-globin expression in different forms of HPFH, some of which are being recreated by therapeutic genome editing.
ISSN:1061-4036
1546-1718
DOI:10.1038/s41588-021-00904-0